Statin use and the risk of developing diabetes: a network meta‐analysis
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Purpose: Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta‐analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices. Methods: We identified studies relevant to our NMA by performing study searches in databases like Embase, Cochrane, and PubMed, published between August 2010 and June 2014. Pre‐2010 studies were identified from bibliography of previously published meta‐analyses. Unpublished study data were found from clinicaltrial.gov. Data synthesis was performed by pairwise meta‐analysis and NMA within a Frequentist framework. Results: Twenty nine trials in which 1 63 039 participants had been randomized were included in this review; among these 1 41 863 were non‐diabetic patients. The direct meta‐analysis showed that statins, as a class, significantly increased the likelihood of developing diabetes by 12% (pooled OR 1.12; 95%CI 1.05–1.21; I 2 36%;p = 0.002; 18 RCTs). In the NMA, atorvastatin 80 mg was associated with a highest risk of diabetes, with OR of 1.34 (95%CI 1.14–1.57) followed by rosuvastatin (OR: 1.17; 95%CI: 1.02–1.35). The ORs (95%CIs) for simvastatin 80 mg, simvastatin, atorvastatin, pravastatin, lovastatin and pitavastatin were 1.21 (0.99–1.49), 1.13 (0.99–1.29), 1.13 (0.94–1.34), 1.04 (0.93–1.16), 0.98 (0.69–1.38) and 0.74 (0.31–1.77), respectively. High‐dose atorvastatin increased the odds of developing diabetes even when compared with pravastatin, simvastatin and low‐dose atorvastatin in the NMA. Conclusions: Based on the results, statins, as a class, increased the risk of diabetes significantly in the pairwise meta‐analysis. Overall, there appears to be a small increased risk of incident diabetes, particularly with more intensive statin therapy, although more data would be valuable to increase the robustness of this interpretation, given that the lower confidence intervals of our study analyses are close to, or just crossing one. Copyright © 2016 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Cited by
Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
Crandall, J. P., Mather, K., Rajpathak, S. N., Goldberg, R. B., Watson, K., Foo, S., Ratner, R., Barrett-Connor, E., & Temprosa, M. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000438 · Cited by 137
Statins and risk of type 2 diabetes: mechanism and clinical implications
Laakso, M., & Fernandes Silva, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1239335 · Cited by 82
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Banerjee, Y., Pantea Stoian, A., Cicero, A. F. G., Fogacci, F., Nikolic, D., Sachinidis, A., Rizvi, A. A., Janez, A., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1988568 · Cited by 54
Metadata
- Authors
- Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2016-06-09
- Volume
- 25
- Issue
- 10
- Pages
- 1131-1149
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2414525849
- Cited by
- 144
- References
- 22
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin use and the risk of developing diabetes: a network meta‐analysis. https://app.cochat.ai/papers/10.1002/pds.4020
- The paper
- Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A. (2016). Statin use and the risk of developing diabetes: a network meta‐analysis. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.4020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.